These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 25623409)

  • 1. Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.
    Worley MJ; Witkiewitz K; Brown SA; Kivlahan DR; Longabaugh R
    Alcohol Clin Exp Res; 2015 Jan; 39(1):93-100. PubMed ID: 25623409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
    Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
    JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
    Greenfield SF; Pettinati HM; O'Malley S; Randall PK; Randall CL
    Alcohol Clin Exp Res; 2010 Oct; 34(10):1803-12. PubMed ID: 20645934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does family history of alcoholism moderate naltrexone's effects on alcohol use?
    Capone C; Kahler CW; Swift RM; O'Malley SS
    J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.
    Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
    Alcohol; 2012 Mar; 46(2):121-31. PubMed ID: 21925828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.
    O'Malley SS; Sinha R; Grilo CM; Capone C; Farren CK; McKee SA; Rounsaville BJ; Wu R
    Alcohol Clin Exp Res; 2007 Apr; 31(4):625-34. PubMed ID: 17374042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial.
    Anton RF; Moak DH; Waid LR; Latham PK; Malcolm RJ; Dias JK
    Am J Psychiatry; 1999 Nov; 156(11):1758-64. PubMed ID: 10553740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between medication adherence and treatment outcomes: the COMBINE study.
    Zweben A; Pettinati HM; Weiss RD; Youngblood M; Cox CE; Mattson ME; Gorroochurn P; Ciraulo D
    Alcohol Clin Exp Res; 2008 Sep; 32(9):1661-9. PubMed ID: 18616687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic moderators of naltrexone's effects on alcohol cue reactivity.
    McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R
    Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cravings as a mediator and moderator of drinking outcomes in the COMBINE study.
    Subbaraman MS; Lendle S; van der Laan M; Kaskutas LA; Ahern J
    Addiction; 2013 Oct; 108(10):1737-44. PubMed ID: 23668624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
    Witkiewitz K; Bowen S; Donovan DM
    J Consult Clin Psychol; 2011 Feb; 79(1):54-63. PubMed ID: 21261434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
    Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
    JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
    Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
    Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the Sweet-Liking Phenotype and Craving for Alcohol With the Response to Naltrexone Treatment in Alcohol Dependence: A Randomized Clinical Trial.
    Garbutt JC; Kampov-Polevoy AB; Kalka-Juhl LS; Gallop RJ
    JAMA Psychiatry; 2016 Oct; 73(10):1056-1063. PubMed ID: 27627782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.
    Mann K; Vollstädt-Klein S; Reinhard I; Leménager T; Fauth-Bühler M; Hermann D; Hoffmann S; Zimmermann US; Kiefer F; Heinz A; Smolka MN
    Alcohol Clin Exp Res; 2014 Nov; 38(11):2754-62. PubMed ID: 25421512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.
    Witkiewitz K; Pearson MR; Hallgren KA; Maisto SA; Roos CR; Kirouac M; Wilson AD; Montes KS; Heather N
    Addiction; 2017 Dec; 112(12):2112-2121. PubMed ID: 28511286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
    Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
    J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
    Ray LA; Hutchison KE
    Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
    Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
    Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.
    Garbutt JC; Kranzler HR; O'Malley SS; Gastfriend DR; Pettinati HM; Silverman BL; Loewy JW; Ehrich EW;
    JAMA; 2005 Apr; 293(13):1617-25. PubMed ID: 15811981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.